Safety of IGIV therapy and infusion-related adverse events.

  title={Safety of IGIV therapy and infusion-related adverse events.},
  author={Mark Ballow},
  journal={Immunologic research},
  volume={38 1-3},
Patients with primary immunodeficiency diseases have been treated with intravenous gammaglobulin (IGIV) for over 20 years. Gamma globulins were first introduced as a therapeutic modality in 1952 by Robert A. Good, who injected gamma globulins by the intramuscular (IM) route to treat patients with X-linked agammaglobulinemia. Subsequently, the clinical indications for gamma globulins therapy expanded from patients with Bruton's disease and other primary immune deficiency disorders to include a… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 36 extracted citations

Similar Papers

Loading similar papers…